85 related articles for article (PubMed ID: 28826084)
1. Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
Qin M; Tian Y; Sun X; Yu S; Xia J; Gong P; Zhang H; Zhao Y
Eur J Med Chem; 2017 Oct; 139():492-502. PubMed ID: 28826084
[TBL] [Abstract][Full Text] [Related]
2. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
3. Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
Qin M; Yan S; Wang L; Zhang H; Tian Y; Zhao Y; Gong P
Bioorg Med Chem; 2017 Mar; 25(6):1778-1786. PubMed ID: 28190652
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Song J; Yoo J; Kwon A; Kim D; Nguyen HK; Lee BY; Suh W; Min KH
PLoS One; 2015; 10(9):e0138823. PubMed ID: 26401847
[TBL] [Abstract][Full Text] [Related]
5. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors.
Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P
Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
Yang TH; Lee CI; Huang WH; Lee AR
Molecules; 2017 May; 22(6):. PubMed ID: 28561780
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
Roth GJ; Heckel A; Colbatzky F; Handschuh S; Kley J; Lehmann-Lintz T; Lotz R; Tontsch-Grunt U; Walter R; Hilberg F
J Med Chem; 2009 Jul; 52(14):4466-80. PubMed ID: 19522465
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
11. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.
Kirkin V; Thiele W; Baumann P; Mazitschek R; Rohde K; Fellbrich G; Weich H; Waltenberger J; Giannis A; Sleeman JP
Int J Cancer; 2004 Dec; 112(6):986-93. PubMed ID: 15386354
[TBL] [Abstract][Full Text] [Related]
12. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyindole carboxylic acid-based inhibitors for receptor-type protein tyrosine protein phosphatase beta.
Zeng LF; Zhang RY; Bai Y; Wu L; Gunawan AM; Zhang ZY
Antioxid Redox Signal; 2014 May; 20(14):2130-40. PubMed ID: 24180557
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel FLT3 kinase inhibitors.
Pauwels D; Klaassen H; Lahortiga I; Kilonda A; Jacobs K; Sweron B; Corbau R; Chaltin P; Marchand A; Cools J
Eur J Med Chem; 2013 May; 63():713-21. PubMed ID: 23567961
[TBL] [Abstract][Full Text] [Related]
15. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
16. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
[TBL] [Abstract][Full Text] [Related]
18. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
19. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
20. Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity.
Ganser C; Lauermann E; Maderer A; Stauder T; Kramb JP; Plutizki S; Kindler T; Moehler M; Dannhardt G
J Med Chem; 2012 Nov; 55(22):9531-40. PubMed ID: 23088521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
